GE HealthCare delivered strong Q4 and full-year 2025 results, exceeding expectations with Q4 revenue of $5.7 billion (4.8% organic growth) and full-year revenue of $20.6 billion (3.5% organic growth). Adjusted EPS for the quarter was $1.44, down 0.7% due to tariffs, but grew 11% excluding those costs; full-year adjusted EPS reached $4.59. The company achieved a record backlog of $21.8 billion, up $2 billion year-over-year, driven by double-digit growth in Pharmaceutical Diagnostics and mid-single-digit growth in Imaging. Strategic highlights include the planned acquisition of IntelliRed to boost digital capabilities and the advancement of the Heartbeat business system to drive productivity. For 2026, GEHC guides for 3-4% organic revenue growth and adjusted EPS of $4.95 to $5.15, reflecting confidence in innovation and margin expansion despite a cautious outlook on China.
| Metric | Value | Change |
|---|---|---|
| Q4 Revenue | $5.7 billion | +4.8% organic |
| FY 2025 Revenue | $20.6 billion | +3.5% organic |
| Q4 Adjusted EPS | $1.44 | -0.7% (or +11% ex-tariffs) |
| FY 2025 Adjusted EPS | $4.59 | +2.2% (or +12% ex-tariffs) |
| Q4 Book-to-Bill | 1.06x | N/A |
| Backlog | $21.8 billion | +$2.0 billion YoY |
| Q4 Free Cash Flow | $916 million | +$105 million YoY |
| FY 2025 Free Cash Flow | $1.5 billion | 72% conversion |
GEHC is leveraging a robust innovation portfolio, highlighted by a 55% vitality rate, to drive future growth. New products like Photon Counting CT and Total Body Pet are expected to drive 1-2 points of additional sales growth in the medium term. Management emphasized that these products have higher gross margins than their predecessors, which will support margin expansion as they ramp through 2027.
The proprietary 'Heartbeat' business system is driving operational excellence and margin expansion. In 2025, it helped reduce past-due backlog by 25% on average monthly versus the prior year. This system is also central to tariff mitigation efforts, enabling supply chain shifts such as moving a PETCT line from the Middle East to the US, which supports the 50-80 basis points of margin expansion guided for 2026.
The company is actively shifting its business mix towards recurring revenue through strategic M&A and service attach rates. The planned acquisition of IntelliRed ($270M revenue, >30% EBITDA) is a prime example, aimed at enhancing cloud-first imaging ecosystems. Additionally, new sophisticated equipment like Total Body Pet commands higher service attach rates, creating a 'flywheel effect' for sustainable revenue.
Pharmaceutical Diagnostics emerged as a key growth driver, delivering double-digit organic sales growth of 12.7% in Q4. This strength, combined with the successful ramp of FERCATO—where weekly doses reached 220 in late January—positions the segment for continued robust growth. Management's reaffirmation of the $500M FERCATO revenue target by 2028 signals strong conviction in this high-growth molecular diagnostics vertical.
Tariffs presented a significant financial drag in 2025, impacting EBIT by $245 million and EPS by $0.43. While management expects the impact to be 'less than 2025' in the coming year, they anticipate the largest impact will hit in Q1 2026. The ongoing need for supply chain reconfiguration to mitigate these costs introduces execution risk and potential margin volatility.
The company is guiding for a revenue decline in China for 2026, reflecting a 'prudent' or cautious stance on the market. Q4 2025 was noted as the most challenging comparison, and while tender win rates are improving, the timing of order issuance remains uncertain. This contraction in a major market poses a risk to the top-line growth guidance of 3-4%.
Order growth decelerated significantly in Q4 to 2%, down from 5.6% in the prior year. While management points to a record backlog and 'stacked' two-year growth to smooth the comparison, the slowdown in order intake—attributed to tough comps and regulatory timing—raises concerns about the sustainability of revenue growth into late 2026 if new product approvals are delayed.
The Patient Care Solutions (PCS) segment exhibited weakness, with organic revenue declining 1.1% year-over-year in Q4. While margins improved sequentially from a product hold, the year-over-year decline driven by life support solutions highlights uneven performance across the portfolio and reliance on specific product cycles for stability.
Overall: Management conveyed a tone of resilience and disciplined execution throughout the call. They acknowledged the significant headwinds from tariffs and the challenging environment in China but emphasized the effectiveness of their mitigation strategies and the strength of their backlog. There was a distinct shift to high confidence when discussing the product pipeline and long-term targets, contrasting with the prudent caution used for near-term macro guidance.
Confidence: HIGH - Management reaffirmed long-term targets like the $500M FERCATO revenue goal and provided specific 2026 guidance showing EPS growth acceleration despite macro headwinds. Their use of definitive language regarding the 'record backlog' and 'innovation renaissance' supports a high confidence assessment.
3% to 4%
$4.95 to $5.15
15.8% to 16.1%
Approximately $1.7 billion
2% to 3%
Hedging & Uncertainty: Management employed hedging language primarily around macroeconomic factors and specific product timing, using qualifiers like 'prudent approach,' 'cautious outlook,' and 'anticipate' regarding China and 2026 guidance. They used temporal hedges such as 'start to see the benefit' and 'impact later this year' to manage expectations for new product contributions, effectively pushing heavy growth metrics to 2027. However, they reduced hedging significantly when discussing operational execution ('Heartbeat') and long-term targets like FERCATO, using direct phrases like 'confidence remains intact' and 'committed to those midterm targets.'
We're taking a prudent approach to China when we put together this guidance. - Jay Saccaro, Vice President and CFO
Our confidence in our ability to deliver $500 million or more in Vorcado revenue by year-end 2028 remains intact. - Peter Arduini, President and CEO
We're going slow to go fast to help ensure customers have a high-quality experience. - Peter Arduini, President and CEO
We expect those products along with Orcato to help drive one to two points of additional sales growth. - Jay Saccaro, Vice President and CFO
We entered 2026 with strong momentum. - Peter Arduini, President and CEO
Analyst Sentiment: Analysts were generally inquisitive about the disconnect between strong backlog growth and slower order growth, as well as the specific mechanics of the China slowdown and the FERCATO ramp. There was a focus on understanding the puts and takes for 2026 guidance.
Management Responses: Management was well-prepared and defensive regarding the order growth metrics, emphasizing the 'stacked' two-year growth rate and the record backlog to validate the business health. They were transparent about the 'go slow' strategy for FERCATO to ensure quality, and they maintained a disciplined tone regarding China, refusing to speculate on upside despite noting positive commercial trends.
Discussion on the composition of the 2% order growth in Q4 and the outlook for orders/book-to-bill in 2026, with management highlighting a difficult Q1 comp but acceleration in H2 due to NPIs.
Detailed color on FERCATO (Vorcado) supply, specifically the 'go slow to go fast' strategy to ensure 95% on-time delivery metrics before ramping patient doses.
Analysis of the China assumptions baked into the 2026 guidance, with management confirming a decline is budgeted but noting improved VBP win rates.
Inquiries into the timing of revenue contributions from Photon Counting CT and other NPIs, with management clarifying that the bulk of the impact is expected in 2027.
GE HealthCare is executing a successful multi-year turnaround strategy anchored in operational rigor (Heartbeat) and a robust innovation cycle. The company delivered solid 2025 results despite significant tariff headwinds, demonstrating the resilience of its business model. The record backlog of $21.8 billion provides strong revenue visibility, while the guidance for 8-12% EPS growth in 2026 signals confidence in margin expansion and productivity gains. Although near-term top-line growth appears conservative (3-4%) due to a deliberate cautious stance on China, the underlying fundamentals—double-digit growth in Pharma Diagnostics, high-margin new product launches, and the accretive IntelliRed acquisition—create a compelling setup for sustainable double-digit earnings growth. The risk of order growth deceleration is mitigated by the robust backlog and the pending wave of regulatory approvals expected to drive orders in late 2026 and 2027.
Management described the US capital environment as 'solid' and 'robust,' citing a recent survey of top 50 customers where many anticipate investment increases driven by an aging installed base and strong procedure trends.
The company is taking a 'prudent approach' to China, budgeting for a decline in 2026 due to difficult prior-year comparisons and tender delays, despite seeing some improvements in VBP win rates.
Management noted that the European market has 'continued to improve' over the past couple of quarters, with orders recovering in many geographies.